嵌合抗原受体T细胞免疫治疗多发性骨髓瘤:当前数据与潜在临床应用综述
多发性骨髓瘤(MM)多数患者仍不可治愈,免疫逃逸是关键发病过程,移植后骨髓瘤特异性免疫应答与更好预后相关。过继T细胞疗法可能改善抗骨髓瘤免疫并带来持久缓解。针对MM的CAR-T疗法处于早期临床开发阶段,抗BCMA CAR-T在早期临床试验中结果最佳,毒性包括细胞因子释放综合征(CRS)和神经毒性。
要点
- MM多数患者仍不可治愈,免疫逃逸是关键发病过程。
- 抗BCMA CAR-T在早期临床试验中显示最佳结果。
- CAR-T相关毒性包括细胞因子释放综合征和神经毒性。
核心结论
- 针对MM的CAR-T疗法处于早期临床开发阶段,抗BCMA CAR-T在早期临床试验中结果最佳。
研究设计与样本
- 综述,总结当前CAR-T治疗MM的临床数据与潜在临床应用。
主要发现
- 自体和异基因干细胞移植后出现骨髓瘤特异性免疫应答与更好预后相关。
- 过继T细胞疗法可能改善特异性抗骨髓瘤免疫,导致持久缓解。
- 抗BCMA CAR-T在早期临床试验中显示最佳结果,毒性包括细胞因子释放综合征和神经毒性。
关键数值与推荐
- 当前CAR-T研究领域包括使用基因编辑增强有效性和安全性、CAR-T与其他疗法(免疫调节药物、检查点抑制剂)整合以及CAR-T靶向多种抗原。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients despite significant improvements achieved with modern therapy. Tumor evasion is a key process in the pathogenesis of MM and a compromised immune system is associated with more aggressive forms of the disease. In contrast, the emergence of myeloma-specific immune responses after both autologous and allogeneic stem cell transplantation is associated with better prognosis. Adoptive T cell therapies may improve specific anti-myeloma immunity resulting in long-lasting remissions. CAR T cell therapies for MM are at an early stage of clinical development. To date, anti-BCMA CAR T cells have shown the greatest results in early-phase clinical trials. Toxicities have included cytokine release syndrome (CRS) and neurotoxicity. Current areas of research in CAR T cell therapies include the use of gene-editing to enhance their effectiveness and safety, the integration of CAR T cells with other therapies (immunomodulatory drugs, checkpoint inhibitors) and CAR T cells to target multiple antigens.
引用
- Susanibar Adaniya SP, Cohen AD, Garfall AL, et al. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. Am J Hematol. 2019. PMID: 30730071. doi:10.1002/ajh.25428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。